Media headlines about LivaNova PLC (NASDAQ:LIVN) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LivaNova PLC earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.5472892059493 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Several brokerages recently issued reports on LIVN. Needham & Company LLC lifted their price objective on LivaNova PLC to $93.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity reaffirmed a “hold” rating and set a $76.00 price objective on shares of LivaNova PLC in a report on Tuesday, November 14th. Zacks Investment Research raised LivaNova PLC from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a report on Thursday, November 9th. BTIG Research reaffirmed a “hold” rating on shares of LivaNova PLC in a report on Tuesday, November 7th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $85.00 price objective on shares of LivaNova PLC in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $79.14.

LivaNova PLC (NASDAQ LIVN) traded up $0.06 during midday trading on Tuesday, hitting $84.38. The stock had a trading volume of 442,100 shares, compared to its average volume of 390,525. LivaNova PLC has a 12 month low of $42.97 and a 12 month high of $84.91. The firm has a market capitalization of $4,070.00 and a PE ratio of 24.30. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.42 and a current ratio of 2.03.

LivaNova PLC (NASDAQ:LIVN) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.17. LivaNova PLC had a return on equity of 9.33% and a net margin of 4.63%. The company had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. During the same period in the previous year, the firm posted $0.78 earnings per share. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. analysts forecast that LivaNova PLC will post 3.33 EPS for the current fiscal year.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $81.39, for a total value of $81,390.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 3,000 shares of company stock valued at $224,520. Insiders own 0.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/21/livanova-plc-livn-earns-news-impact-rating-of-0-19.html.

About LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova PLC (NASDAQ:LIVN)

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.